Buy MONOVISC®

MONOVISC® is a single-injection hyaluronic acid-based viscosupplement designed for the treatment of pain associated with osteoarthritis of the knee. It is composed of ultra-pure, high molecular weight sodium hyaluronate derived from a non-animal source, making it highly biocompatible and well tolerated.

When injected into the affected joint, MONOVISC® replenishes synovial fluid, which becomes degraded in osteoarthritic conditions. The hyaluronic acid in MONOVISC® acts as a lubricant and shock absorber, reducing friction and allowing smoother, pain-free movement. Additionally, it provides a cushioning effect that helps protect joint tissues and reduces inflammation over time.

MONOVISC® is specifically indicated for:

• Treating knee pain in patients with osteoarthritis who have not responded adequately to conservative therapy (e.g., physical therapy or analgesics)
• Providing sustained joint lubrication and cushioning
• Enhancing mobility and comfort in daily activities

It is a preferred option for patients seeking relief without surgical intervention or those needing an alternative to systemic pain medications.

MONOVISC® stands out in the viscosupplement market for its ease of use, single-injection protocol, and long-lasting effectiveness. It is produced using a patented cross-linking technology that enhances its viscoelastic properties while maintaining safety and tolerability.

Key benefits of MONOVISC® include:

• Single-dose convenience, reducing patient visits
• Non-animal derived HA, minimizing allergy risk
• High molecular weight formulation for optimal performance
• Clinically proven results lasting up to six months
• FDA-approved and CE-marked

MONOVISC® offers a streamlined and effective option for managing osteoarthritis-related joint pain.

Most patients experience relief within days following the injection, with peak improvement occurring after 2 to 4 weeks. Clinical studies show that a single MONOVISC® injection can provide pain relief for up to six months, depending on the severity of osteoarthritis and the patient’s physical activity levels.

Ongoing evaluations may determine the need for reapplication after the therapeutic window ends.

MONOVISC® is generally well tolerated, with a low incidence of adverse events. The product has a strong safety profile due to its high purity and non-animal origin. It is both CE-marked and FDA-approved for intra-articular use.

When administered by trained professionals under sterile conditions, MONOVISC® carries minimal risk. Side effects are rare and usually mild, typically resolving within a few days.